Skip to main content
. 2018 Feb 7;8:2534. doi: 10.1038/s41598-017-18062-x

Figure 1.

Figure 1

Quantification of dominant CD8+ TCR-Vβ+ expansions in T-LGLL and dasatinib-treated CML patients. (A) Gating strategy for the identification of viable CD14− CD19− CD3+ CD8+ cells within PBMCs. (B) Representative flow cytometry plots showing expanded (TCR-Vβ+) and residual (TCR-Vβ−) CD8+ T-cell populations in T-LGLL and dasatinib-treated CML patients. (C) Percent frequencies of dominant CD8+ TCR-Vβ+ expansions in T-LGLL (n = 11) and dasatinib-treated CML patients (n = 10). Statistical comparisons were performed using the Mann-Whitney U test. ***P < 0.0001. Error bars represent SD.